|
|
Vaccine Detail
|
ALVAC(2) Melanoma Multi-antigen Vaccine |
| Vaccine Information |
- Vaccine Name: ALVAC(2) Melanoma Multi-antigen Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007249
- Type: Recombinant vector vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- gp100 (PMEL)
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- CTAG1B
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- Preparation: An avian poxvirus is used as vector to stimulate T-cell response against tumor-associated antigens (Vogel et al., 2010).
- Description: A therapeutic cancer vaccine, based on a replication-defective recombinant canarypox virus (ALVAC) encoding multiple melanoma antigens, with potential immunostimulatory and antineoplastic activities. Vaccination with ALVAC(2) melanoma multi-antigen therapeutic vaccine may stimulate the host immune system to mount an immune response against antigen-expressing melanoma cells, resulting in inhibition of tumor growth and/or metastasis. (NCIT_C73998).
|
| Host Response |
|
|
| References |
NCIT_C73998: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C73998]
Vogel et al., 2010: Vogel TU, Visan L, Ljutic B, Gajewska B, Caterini J, Salha D, Wen T, He L, Parrington M, Cao SX, McNeil B, Sandhu D, Scollard N, Zhang L, Bradley B, Tang M, Lovitt C, Oomen R, Dunn P, Tartaglia J, Berinstein NL. Preclinical qualification of a new multi-antigen candidate vaccine for metastatic melanoma. Journal of immunotherapy (Hagerstown, Md. : 1997). 2010; 33(8); 743-758. [PubMed: 20842062].
|
|
